300357 我武生物
已收盘 07-23 15:00:00
资讯
新帖
简况
我武生物(300357)7月17日主力资金净卖出74.77万元
证券之星 · 07-18
我武生物(300357)7月17日主力资金净卖出74.77万元
“脱敏第一股”状告前金主!
市场资讯 · 07-12
“脱敏第一股”状告前金主!
我武生物:公司会根据法定要求披露2024年上半年相关经营数据
证券之星 · 07-08
我武生物:公司会根据法定要求披露2024年上半年相关经营数据
我武生物(300357)6月28日主力资金净买入424.36万元
证券之星 · 07-01
我武生物(300357)6月28日主力资金净买入424.36万元
我武生物(300357)6月26日主力资金净买入1367.26万元
证券之星 · 06-27
我武生物(300357)6月26日主力资金净买入1367.26万元
我武生物(300357.SZ)2023年年度权益分派:每10股派1.85元 7月3日股权登记
智通财经 · 06-26
我武生物(300357.SZ)2023年年度权益分派:每10股派1.85元 7月3日股权登记
我武生物涨7.14%,西南证券一个月前给出“买入”评级,目标价28.80元
证券之星 · 06-26
我武生物涨7.14%,西南证券一个月前给出“买入”评级,目标价28.80元
独家药品概念盘中拉升,我武生物涨1.41%
自选股智能写手 · 06-26
独家药品概念盘中拉升,我武生物涨1.41%
我武生物:公司不存在上述情况
证券之星 · 06-17
我武生物:公司不存在上述情况
我武生物(300357)6月14日主力资金净卖出904.20万元
证券之星 · 06-17
我武生物(300357)6月14日主力资金净卖出904.20万元
我武生物:公司现任总经理何建明先生是复旦大学博士毕业
证券之星 · 06-16
我武生物:公司现任总经理何建明先生是复旦大学博士毕业
我武生物(300357.SZ):聘任何建明为总经理
智通财经 · 06-13
我武生物(300357.SZ):聘任何建明为总经理
我武生物:公司是一家专业从事过敏性疾病诊断及治疗产品的研发、生产和销售的高科技生物制药企业
证券之星 · 06-07
我武生物:公司是一家专业从事过敏性疾病诊断及治疗产品的研发、生产和销售的高科技生物制药企业
我武生物:公司相关产品的生产量、销售量情况具体请查阅公司的定期报告
证券之星 · 06-06
我武生物:公司相关产品的生产量、销售量情况具体请查阅公司的定期报告
我武生物:公司对于研发项目的投入是根据各研发项目的进展合理规划投入
证券之星 · 06-04
我武生物:公司对于研发项目的投入是根据各研发项目的进展合理规划投入
我武生物(300357)5月29日主力资金净卖出555.69万元
证券之星 · 05-30
我武生物(300357)5月29日主力资金净卖出555.69万元
我武生物:公司目前的客户主要为各地的医药商业公司(医药经营企业),公司的营销模式具体可参见年度报告
证券之星 · 05-20
我武生物:公司目前的客户主要为各地的医药商业公司(医药经营企业),公司的营销模式具体可参见年度报告
我武生物(300357)5月10日主力资金净卖出2688.07万元
证券之星 · 05-13
我武生物(300357)5月10日主力资金净卖出2688.07万元
我武生物:公司2024年第一季度业绩有所恢复,具体经营情况详见2024年第一季度报告
证券之星 · 05-10
我武生物:公司2024年第一季度业绩有所恢复,具体经营情况详见2024年第一季度报告
我武生物:公司子公司干细胞药物在研项目目前处于临床前研究阶段,不涉及糖尿病相关适应症
证券之星 · 05-09
我武生物:公司子公司干细胞药物在研项目目前处于临床前研究阶段,不涉及糖尿病相关适应症
加载更多
公司概况
公司名称:
浙江我武生物科技股份有限公司
所属行业:
医药制造业
上市日期:
2014-01-21
主营业务:
浙江我武生物科技股份有限公司是一家过敏性疾病诊断及治疗产品的研发、生产和销售的高新技术企业。公司主要产品包括粉尘螨滴剂、黄花蒿花粉变应原舌下滴剂、粉尘螨皮肤点刺诊断试剂盒、屋尘螨皮肤点刺诊断试剂盒、“黄花蒿花粉变应原皮肤点刺液”、“白桦花粉变应原皮肤点刺液”、“葎草花粉变应原皮肤点刺液”。
发行价格:
20.05
{"stockData":{"symbol":"300357","market":"SZ","secType":"STK","nameCN":"我武生物","latestPrice":18.82,"timestamp":1721718198000,"preClose":19.74,"halted":0,"volume":6543652,"delay":0,"floatShares":484000000,"shares":524000000,"eps":0.6053,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.92,"latestTime":"07-23 15:00:00","open":19.73,"high":19.74,"low":18.81,"amount":125000000,"amplitude":0.0471,"askPrice":18.82,"askSize":206,"bidPrice":18.81,"bidSize":476,"shortable":0,"etf":0,"ttmEps":0.6053,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721784600000},"adr":0,"adjPreClose":19.74,"symbolType":"stock","openAndCloseTimeList":[[1721698200000,1721705400000],[1721710800000,1721718000000]],"highLimit":21.71,"lowLimit":17.77,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":523584000,"pbRate":4.56,"roa":"--","roe":"3.47%","epsLYR":0.5924,"committee":0.272268,"marketValue":9854000000,"floatMarketCap":9110000000,"peRate":31.09202,"changeRate":-0.0466,"turnoverRate":0.0135,"status":1},"requestUrl":"/m/hq/s/300357","defaultTab":"news","newsList":[{"id":"2452148964","title":"我武生物(300357)7月17日主力资金净卖出74.77万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2452148964","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452148964?lang=zh_cn&edition=full","pubTime":"2024-07-18 09:14","pubTimestamp":1721265273,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年7月17日收盘,我武生物报收于19.5元,上涨2.04%,换手率1.3%,成交量6.32万手,成交额1.23亿元。7月17日的资金流向数据方面,主力资金净流出74.77万元,占总成交额0.61%,游资资金净流入585.8万元,占总成交额4.77%,散户资金净流出511.03万元,占总成交额4.16%。融券方面,融券卖出1.68万股,融券偿还1.72万股,融券余量20.65万股,融券余额402.68万元。我武生物主营业务:过敏性疾病诊断及治疗产品的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071800014170.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300357","BK0028"],"gpt_icon":0},{"id":"2450858109","title":"“脱敏第一股”状告前金主!","url":"https://stock-news.laohu8.com/highlight/detail?id=2450858109","media":"市场资讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450858109?lang=zh_cn&edition=full","pubTime":"2024-07-12 19:37","pubTimestamp":1720784220,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报,权威,专业,及时,全面,助您挖掘潜力主题机会! 浙江德清“女首富”公司状告前股东。 前股东9年前的一次减持行为,引来上市公司一纸诉讼。 7月8日,“脱敏治疗”概念第一股我武生物公告称,公司对IPO之前的前股东上海利合股权投资合伙企业提起诉讼,目前处于诉前调解阶段,涉案金额1096.13万元及利息321.51万元。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/s/2024-07-12/doc-inccwqxr7735076.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2024-07-12/doc-inccwqxr7735076.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["300357","BK0239","BK0028"],"gpt_icon":0},{"id":"2449727203","title":"我武生物:公司会根据法定要求披露2024年上半年相关经营数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2449727203","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449727203?lang=zh_cn&edition=full","pubTime":"2024-07-08 18:02","pubTimestamp":1720432952,"startTime":"0","endTime":"0","summary":"证券之星消息,我武生物07月08日在投资者关系平台上答复投资者关心的问题。比如发布业绩预告,谢谢我武生物董秘:投资者您好,谢谢您的建议,公司会根据法定要求披露2024年上半年相关经营数据。公司将现金分红作为回报股东的重要方式,自上市以来,公司每年以现金方式分配的利润均大于当年归属于上市公司股东净利润的30%,回报全体股东。截至目前,公司累计实施的现金分红总额近8亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070800025018.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357","BK0239","BK0028"],"gpt_icon":0},{"id":"2448933171","title":"我武生物(300357)6月28日主力资金净买入424.36万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2448933171","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448933171?lang=zh_cn&edition=full","pubTime":"2024-07-01 09:21","pubTimestamp":1719796878,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年6月28日收盘,我武生物报收于20.22元,下跌2.65%,换手率1.62%,成交量7.83万手,成交额1.61亿元。6月28日的资金流向数据方面,主力资金净流入424.36万元,占总成交额2.64%,游资资金净流出734.67万元,占总成交额4.57%,散户资金净流入310.31万元,占总成交额1.93%。融券方面,融券卖出6.91万股,融券偿还2100.0股,融券余量34.65万股,融券余额700.61万元。我武生物主营业务:过敏性疾病诊断及治疗产品的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070100003689.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357","BK0028","BK0239"],"gpt_icon":0},{"id":"2446329006","title":"我武生物(300357)6月26日主力资金净买入1367.26万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2446329006","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446329006?lang=zh_cn&edition=full","pubTime":"2024-06-27 09:13","pubTimestamp":1719450832,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年6月26日收盘,我武生物报收于21.32元,上涨7.14%,换手率2.31%,成交量11.17万手,成交额2.32亿元。6月26日的资金流向数据方面,主力资金净流入1367.26万元,占总成交额5.88%,游资资金净流出1500.53万元,占总成交额6.46%,散户资金净流入133.28万元,占总成交额0.57%。融券方面,融券卖出4.42万股,融券偿还1.18万股,融券余量21.37万股,融券余额455.6万元。我武生物主营业务:过敏性疾病诊断及治疗产品的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062700013464.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357","BK0239","BK0028"],"gpt_icon":0},{"id":"2446918364","title":"我武生物(300357.SZ)2023年年度权益分派:每10股派1.85元 7月3日股权登记","url":"https://stock-news.laohu8.com/highlight/detail?id=2446918364","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446918364?lang=zh_cn&edition=full","pubTime":"2024-06-26 19:47","pubTimestamp":1719402469,"startTime":"0","endTime":"0","summary":"智通财经APP讯,我武生物(300357.SZ)发布公告,公司2023年年度权益分派方案为:以公司现有总股本为基数,向全体股东每10股派1.85元人民币现金(含税),本次权益分派股权登记日为:2024年7月3日,除权除息日为:2024年7月4日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1141059.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0028","300357"],"gpt_icon":0},{"id":"2446356945","title":"我武生物涨7.14%,西南证券一个月前给出“买入”评级,目标价28.80元","url":"https://stock-news.laohu8.com/highlight/detail?id=2446356945","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446356945?lang=zh_cn&edition=full","pubTime":"2024-06-26 16:26","pubTimestamp":1719390402,"startTime":"0","endTime":"0","summary":"今日我武生物涨7.14%,收盘报21.32元。2024年4月29日,西南证券研究员杜向阳,王彦迪发布了对我武生物的研报《一季度收入提速》,该研报对我武生物给出“买入”评级,认为其目标价为28.8元,现价距离目标价尚有35.08%的涨幅空间。研报中预计2024-2026年归母净利润分别为3.8亿元、4.8亿元、5.9亿元,对应动态PE分别为33倍、26倍、21倍。我武生物系我国脱敏药物龙头,给予公司2024年40倍PE,对应目标价为28.80元,维持“买入”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062600031765.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357","600369"],"gpt_icon":0},{"id":"2446100383","title":"独家药品概念盘中拉升,我武生物涨1.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2446100383","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446100383?lang=zh_cn&edition=full","pubTime":"2024-06-26 09:48","pubTimestamp":1719366498,"startTime":"0","endTime":"0","summary":"06月26日,独家药品概念盘中拉升,截至09点48分,独家药品概念整体指数上涨0.51%,报771.530点。从个股上来看,该概念的成分股中,我武生物涨1.41%,甘李药业、君实生物-U、新华制药涨幅居前。从资金上来看,截止发稿,独家药品概念概念主力净流入为-3648.17万,其中甘李药业受到资金热捧,主力净流入279.74万;拉长时间线来看,该板块近20日主力资金净流入-49.16亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062609481896816cb9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062609481896816cb9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","603087","300357","BK0028"],"gpt_icon":0},{"id":"2444168457","title":"我武生物:公司不存在上述情况","url":"https://stock-news.laohu8.com/highlight/detail?id=2444168457","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444168457?lang=zh_cn&edition=full","pubTime":"2024-06-17 19:01","pubTimestamp":1718622090,"startTime":"0","endTime":"0","summary":"证券之星消息,我武生物(300357)06月17日在投资者关系平台上答复投资者关心的问题。投资者:董秘你好,2024年6月11日平安乌兰浩特官网通报,破获一起医药领域虚开发票数十亿金额,设计一千多家企业,请问贵司有没有涉及到本企业,本企业有没有虚开发票行为?是否存在相关风险?谢谢!我武生物董秘:投资者您好!公司不存在上述情况。谢谢您的关注。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061700023254.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","300357"],"gpt_icon":0},{"id":"2444900839","title":"我武生物(300357)6月14日主力资金净卖出904.20万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2444900839","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444900839?lang=zh_cn&edition=full","pubTime":"2024-06-17 09:17","pubTimestamp":1718587079,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年6月14日收盘,我武生物报收于21.95元,下跌3.73%,换手率3.27%,成交量15.83万手,成交额3.41亿元。6月14日的资金流向数据方面,主力资金净流出904.2万元,占总成交额2.65%,游资资金净流出2722.16万元,占总成交额7.97%,散户资金净流入3626.36万元,占总成交额10.62%。融券方面,融券卖出5.26万股,融券偿还9300.0股,融券余量25.44万股,融券余额558.4万元。我武生物主营业务:过敏性疾病诊断及治疗产品的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061700001823.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","300357"],"gpt_icon":0},{"id":"2443921328","title":"我武生物:公司现任总经理何建明先生是复旦大学博士毕业","url":"https://stock-news.laohu8.com/highlight/detail?id=2443921328","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443921328?lang=zh_cn&edition=full","pubTime":"2024-06-16 18:00","pubTimestamp":1718532033,"startTime":"0","endTime":"0","summary":"证券之星消息,我武生物(300357)06月16日在投资者关系平台上答复投资者关心的问题。投资者:公司拟任命何建明为总经理,请问何总毕业于哪所高校?谢谢!我武生物董秘:投资者您好!公司现任总经理何建明先生是复旦大学博士毕业。感谢您的关注。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061600001657.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357","BK0239","BK0028"],"gpt_icon":0},{"id":"2443868574","title":"我武生物(300357.SZ):聘任何建明为总经理","url":"https://stock-news.laohu8.com/highlight/detail?id=2443868574","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443868574?lang=zh_cn&edition=full","pubTime":"2024-06-13 16:53","pubTimestamp":1718268784,"startTime":"0","endTime":"0","summary":"智通财经APP讯,我武生物(300357.SZ)发布公告,公司董事会于近日收到公司总经理胡赓熙提交的辞职报告,因个人原因,胡赓熙向公司董事会申请辞去公司总经理职务(原任期至2025年12月27日止),辞去上述职务后,胡赓熙将继续在公司担任董事长及董事会专门委员会相关委员职务。经提名委员会提名,公司第五届董事会第七次会议审议通过《关于聘任公司总经理的议案》,同意聘任何建明为公司总经理,任期至第五届董事会期满日止。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1134780.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0239","300357"],"gpt_icon":0},{"id":"2441805310","title":"我武生物:公司是一家专业从事过敏性疾病诊断及治疗产品的研发、生产和销售的高科技生物制药企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2441805310","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441805310?lang=zh_cn&edition=full","pubTime":"2024-06-07 18:02","pubTimestamp":1717754544,"startTime":"0","endTime":"0","summary":"证券之星消息,我武生物(300357)06月07日在投资者关系平台上答复投资者关心的问题。投资者:公司未来利润增长点?我武生物董秘:投资者您好!公司是一家专业从事过敏性疾病诊断及治疗产品的研发、生产和销售的高科技生物制药企业。目前,公司在国内获准上市的药品包括粉尘螨滴剂、黄花蒿花粉变应原舌下滴剂等。感谢您的关注。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060700036964.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357","BK0028","BK0239"],"gpt_icon":0},{"id":"2441179194","title":"我武生物:公司相关产品的生产量、销售量情况具体请查阅公司的定期报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2441179194","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441179194?lang=zh_cn&edition=full","pubTime":"2024-06-06 18:02","pubTimestamp":1717668138,"startTime":"0","endTime":"0","summary":"证券之星消息,我武生物(300357)06月06日在投资者关系平台上答复投资者关心的问题。投资者:请问公司新增产能情况?我武生物董秘:投资者你好。公司相关产品的生产量、销售量情况具体请查阅公司的定期报告。谢谢您的关注!以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060600036831.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300357","BK0028"],"gpt_icon":0},{"id":"2440400745","title":"我武生物:公司对于研发项目的投入是根据各研发项目的进展合理规划投入","url":"https://stock-news.laohu8.com/highlight/detail?id=2440400745","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440400745?lang=zh_cn&edition=full","pubTime":"2024-06-04 18:04","pubTimestamp":1717495447,"startTime":"0","endTime":"0","summary":"证券之星消息,我武生物06月04日在投资者关系平台上答复投资者关心的问题。请问公司十大股东有没有通过转融通卖出股票?截止2024年第一季度末,公司前10名股东参与转融通业务出借股份情况请查阅公司2024年第一季度报告。公司对于研发项目的投入是根据各研发项目的进展合理规划投入。截止目前,公司主要产品无提价计划。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060400034929.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300357","BK0028"],"gpt_icon":0},{"id":"2439363717","title":"我武生物(300357)5月29日主力资金净卖出555.69万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2439363717","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439363717?lang=zh_cn&edition=full","pubTime":"2024-05-30 09:23","pubTimestamp":1717032212,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年5月29日收盘,我武生物报收于23.76元,下跌1.78%,换手率0.95%,成交量4.62万手,成交额1.1亿元。5月29日的资金流向数据方面,主力资金净流出555.69万元,占总成交额5.04%,游资资金净流出2123.54万元,占总成交额19.25%,散户资金净流入2679.23万元,占总成交额24.29%。融券方面,融券卖出7800.0股,融券偿还2.79万股,融券余量35.67万股,融券余额847.51万元。我武生物主营业务:过敏性疾病诊断及治疗产品的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024053000012708.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","300357"],"gpt_icon":0},{"id":"2436173240","title":"我武生物:公司目前的客户主要为各地的医药商业公司(医药经营企业),公司的营销模式具体可参见年度报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2436173240","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2436173240?lang=zh_cn&edition=full","pubTime":"2024-05-20 18:02","pubTimestamp":1716199332,"startTime":"0","endTime":"0","summary":"公司目前的客户主要为各地的医药商业公司,公司的营销模式具体可参见年度报告。投资者:董秘您好,我建议公司来内蒙古赤峰 鄂尔多斯市 山西北部 陕西北部等众多地区调研,这里地方病是过敏性鼻炎并发眼睛奇痒咳簌哮喘,赤峰4-5月份发病比例人口已达70%,总人口400万,只要离开这里到关内就好,其导致原因不明,我们期望贵公司来采空气样本筛查过敏原,对症开发特效药。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052000019564.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK1161","BK1515","159938","300357","09939","BK1574"],"gpt_icon":0},{"id":"2435607993","title":"我武生物(300357)5月10日主力资金净卖出2688.07万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2435607993","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435607993?lang=zh_cn&edition=full","pubTime":"2024-05-13 09:20","pubTimestamp":1715563220,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年5月10日收盘,我武生物报收于25.53元,下跌4.67%,换手率2.6%,成交量12.6万手,成交额3.27亿元。5月10日的资金流向数据方面,主力资金净流出2688.07万元,占总成交额8.21%,游资资金净流出966.29万元,占总成交额2.95%,散户资金净流入3654.36万元,占总成交额11.17%。融券方面,融券卖出10.96万股,融券偿还7.54万股,融券余量46.49万股,融券余额1186.88万元。我武生物主营业务:过敏性疾病诊断及治疗产品的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051300001937.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","300357"],"gpt_icon":0},{"id":"2434971858","title":"我武生物:公司2024年第一季度业绩有所恢复,具体经营情况详见2024年第一季度报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2434971858","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434971858?lang=zh_cn&edition=full","pubTime":"2024-05-10 20:01","pubTimestamp":1715342475,"startTime":"0","endTime":"0","summary":"证券之星消息,我武生物05月10日在投资者关系平台上答复投资者关心的问题。二季度以来是否延续了销售趋势我武生物董秘:投资者您好,公司2024年第一季度业绩有所恢复,具体经营情况详见2024年第一季度报告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051000042089.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","300357"],"gpt_icon":0},{"id":"2434106440","title":"我武生物:公司子公司干细胞药物在研项目目前处于临床前研究阶段,不涉及糖尿病相关适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2434106440","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434106440?lang=zh_cn&edition=full","pubTime":"2024-05-09 18:02","pubTimestamp":1715248928,"startTime":"0","endTime":"0","summary":"证券之星消息,我武生物05月09日在投资者关系平台上答复投资者关心的问题。其他还有什么方向?公司子公司干细胞药物在研项目目前处于临床前研究阶段,不涉及糖尿病相关适应症。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050900032785.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","300357"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2014-01-21","address":"浙江省湖州市德清县武康镇志远北路636号","stockEarnings":[{"period":"1week","weight":-0.0152},{"period":"1month","weight":-0.0773},{"period":"3month","weight":-0.1832},{"period":"6month","weight":-0.209},{"period":"1year","weight":-0.4539},{"period":"ytd","weight":-0.3449}],"companyName":"浙江我武生物科技股份有限公司","boardCode":"AI0027","perCapita":"17652股","boardName":"医药制造业","registeredCapital":"52358万元","compareEarnings":[{"period":"1week","weight":-0.0205},{"period":"1month","weight":-0.0276},{"period":"3month","weight":-0.0425},{"period":"6month","weight":0.0032},{"period":"1year","weight":-0.0786},{"period":"ytd","weight":-0.02}],"survey":" 浙江我武生物科技股份有限公司是一家过敏性疾病诊断及治疗产品的研发、生产和销售的高新技术企业。公司主要产品包括粉尘螨滴剂、黄花蒿花粉变应原舌下滴剂、粉尘螨皮肤点刺诊断试剂盒、屋尘螨皮肤点刺诊断试剂盒、“黄花蒿花粉变应原皮肤点刺液”、“白桦花粉变应原皮肤点刺液”、“葎草花粉变应原皮肤点刺液”。","serverTime":1721755680552,"listedPrice":20.05,"stockholders":"27422人(较上一季度增加1.19%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"我武生物(300357)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供我武生物(300357)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"我武生物,300357,我武生物股票,我武生物股票老虎,我武生物股票老虎国际,我武生物行情,我武生物股票行情,我武生物股价,我武生物股市,我武生物股票价格,我武生物股票交易,我武生物股票购买,我武生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"我武生物(300357)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供我武生物(300357)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}